protected 22/23 non-human primates for over 3 1/2 years and 5/6
non-vaccinated controls died of AIDS post-AIDS virus infection.
-- GeoVax AIDS vaccines are designed to elicit protective antibodies
(Ab) as well as protective T cells (white blood cells) against the
AIDS virus. The Merck vaccine stimulates only T cells for providing
protection and does not include the Env protein of HIV which is the
target for protective antibody (Ab).
-- Protective Ab has been difficult to elicit with HIV/AIDS vaccines.
GeoVax has approached this challenge by vaccinating with the natural
form of Env (HIV envelope antigens) under conditions that elicit
tightly binding Ab. GeoVax studies in non-human primates clearly show
this Ab correlates with protection.
-- GeoVax vaccines use an attenuated smallpox vaccine to provide pulses
of HIV proteins (antigen) to stimulate protective anti-AIDS vaccine
responses. Pulses of antigen from the GeoVax vaccines elicit T cell
responses that rapidly mobilize and then contract into a state called
"central memory" from which they rapidly expand to fight the
appearance of HIV.
-- In November, GeoVax announced excellent safety and immunogenicity data
from its full-dose HIV/AIDS vaccine human trial which began in
September 2006. This full-dose trial is the second in a series of four
Phase 1 human trials designed to test the safety and immunogenicity of
the GeoVax HIV/AIDS vaccines. Involving 36 participants of which 30
received vaccine and 6 received placebo, this trial protocol included
vaccination with two full-doses of GeoVax's DNA vaccine to prime the
immune response followed by two full-doses of GeoVax's MVA vaccine to
boost the immune response. GeoVax's DNA and MVA vaccines express o
|SOURCE GeoVax Labs, Inc.|
Copyright©2008 PR Newswire.
All rights reserved